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H3K27me3 and H3K4me3 histone modiﬁcations. We showed that, for a set of genes highly enriched with
H3K27me3 both in cancer and normal cells, CGI promoters were aberrantly hypermethylated only in cancer
cells in comparison with normal cells. In contrast, such aberrant CGI hypermethylation in cancer promoters
that were deﬁcient of H3K27me3 was not notable. Furthermore, we conﬁrmed that these genes were
consistently hypermethylated in TCGA primary cancer cells. These works support the association between
H3K27me3 andDNAmethylationmarks for speciﬁc cancer genes andwill spur futurework on combined histone
and DNA methylation that could deﬁne cancer's epigenetic abnormalities.
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Epigenetic information comprises histone modiﬁcations [1] and DNA
methylation [2] that can substantially inﬂuence chromatin structure
and DNA accessibility [3,4]. In the last decade, the study of epigenetic
mechanisms has been highlighted in cancer causation, progression and
treatment as an alternative for genetic defects [5]. Especially, aberrant
DNA hypermethylation of CpG island (CGI) promoters is associated
with transcriptional repression of many tumor suppressor genes that
can lead to tumor progression in many cancers. Although this model
has been hugely inﬂuential [6], the signiﬁcance of hypermethylation at
CGIs in cancer has long been debated as well [7,8]. Recently, a research
group has observed that genes that are hypermethylated and repressed
in cancers were also repressed in pre-cancerous tissues even though
their promoters are hypomethylated [9,10]. Another research groupressive complex; H3K27me3,
, colon adenocarcinoma; PRAD,
oma; RPKM, Reads Per Kb per
ghts reserved.found that many genes with de novo promoter hypermethylation in
colon cancer were among the subset of genes that were bound with
both the repressingH3K27me3 and the activatingH3K4me3 in embryon-
ic stem cells and adult stem/progenitor cells [11,12]. H3K27me3 is
catalyzed by the SET domain histone methyltransferase EZH2, a compo-
nent protein of the Polycomb-repressive complex (PRC). It was known
that genes that are targeted and repressed by PRC are also poised for
activation in pluripotent cells [13]. It was also discovered by using
chromatin immunoprecipitation in a previous study that binding of
DNA methyltransferases (DNMTs) to several EZH2-repressed genes
depended on the presence of EZH2 [14]. These observations suggested
that promoter hypermethylation in cancers might be associated with
PRC target genes. However, de novo DNA methylation without PRC
occupancy or de novo PRC occupancy without DNA methylation did
exist as well [15].
Recently, a simple and effective new method termed ChIP-BS-seq
(chromatin immunoprecipitation followed by bisulﬁte sequencing)
was developed, enabling direct examination of the methylation status
of DNA sequences immunoprecipitated by ChIP for speciﬁc histone
modiﬁcations [16,17]. Therefore, we took advantage of this new ChIP-
BS-seq technology and applied it to examine trimethylation of histone
H3 lysine 27 (H3K27me3) and histone H3 lysine 4 (H3K4me3) proﬁles
for a normal cell line (YH lymphoblastoid) and three cancer cell lines
(one cervical cancer cell line (HeLa) and two gastric cancer (GC) cell
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BS-seq data for a normal and two cancer cell lines from previous studies
[16,17], thus, enabling examination of 7 cell lines in total.
By overall comparison between these cancer and normal cell lines, we
showed that a set of genes commonly enriched with H3K27me3 marks
both in cancer and normal cells presented aberrant hypermethylation of
promoter CGIs in cancers, but hypomethylated state is maintained in
the normal cells. Gene ontology analyses suggested that these genes
were highly enriched in ion transport or cellular ion homeostasis
pathway, which were reported frequently in the study of carcinogenesis
and cancer metastasis.
Furthermore, we obtained data from primary cancers in the Cancer
Genome Atlas (TCGA), and conﬁrmed that some highly methylated
genes in cancer cells were also signiﬁcantly hypermethylated in TCGA
data for primary cancers. By combining our cell line methylation data
with TCGA data, we discovered new genes that possess signiﬁcantly dif-
ferent methylation patterns between cancer and normal tissues.2. Materials and methods
2.1. Cell acquisition
A lymphoblastoid cell line was generated from a male Han Chinese
individual (YH), whose genome sequence was reported previously [18].
Two human gastric cancer cell lines (BGC-823 and AGS) were provided
by Beijing Tumor Hospital; the HeLa cell line was purchased from the
American Type Culture Collection (ATCC). Cells were cultured with
RPMI1640 (Gibco C22400500BT) supplemented with 10% fetal bovine
serum (Gibco 12657–029) in a humidiﬁed incubator with 5% CO2 at
37 °C.2.2. Chromatin immunoprecipitation sequencing (ChIP-seq)
Cells were precipitated by centrifugation, and the supernatant was
removed. For each ChIP assay, approximately 5 × 106 cells were used.
DNA and proteins were cross-linked with 1% formaldehyde in 10 ml
PBS at 37 °C for 10 min, and then the cells were washed with pre-
cooled PBS with 0.5% bovine serum and by PBS supplemented with pro-
tease inhibitor compound (PIC). The cells were collected by centrifuga-
tion at 850 rpm for 3 min after each wash. The cells were resuspended
in 200 μl ice-cold lyses buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl,
plus PIC) and then thawed on ice for 10 min to allow cell lyses. The
cell lysate was sonicated for 180 s using BioruptorTM 200 (pulses: 30 s
on/30 s off) to generate chromatin fragments of size range from 100 to
700 bp. As input, one-tenth of the sonicated chromatin sample was
separated. The remaining chromatin was immunoprecipitated in ChIP
dilution buffer (1% Triton, 2 mM EDTA, 150 mM NaCl, 20 mM Tris–HCl)
with 4 μg of antibody against H3K4me3 (Millipore; 17–614) or
H3K27me3 (Millipore; 17–622) that has beenpre-incubatedwithprotein
A/G magnetic beads (Invitrogen; 10003D). The immunoprecipitation
reaction was incubated overnight at 4 °C and the beads were washed
twice with each of the following buffers at 4 °C: RIPA buffer (10 mM
Tris, 1 mM EDTA, 0.1% SDS, 0.1% Na-deoxycholate, 0.1% Triton X-100);
RIPA buffer plus 0.3 M NaCl; LiCl buffer (0.25 M LiCl, 0.5% NP-40, 0.5%
Na-deoxycholate) and TE buffer. The reaction tubewas placed in amag-
netic rack to capture the beads. The bounded DNA was eluted from the
beads with elution buffer (1% SDS, 0.1 M NaHCO3) at 65 °C for 2–3 h.
The same procedure was performed for the input sample. The immu-
noprecipitated DNA was puriﬁed by phenol-chloroform extraction and
precipitated with ethanol and glycogen. Successful immunoprecipitation
was veriﬁed by qPCR using input as background. The obtained high-
quality DNA was subjected to library preparation and sequenced on
Illumina Hiseq 2000 using a standard pair-end 50 bp (PE50) sequencing
protocol.2.3. Library construction for bisulﬁte-sequencing of ChIP-ed DNA
The ChIP DNA (60 ng) ends was repaired in a 100 μl reaction
containing 1XT4 PNK buffer, 3 units T4 DNA polymerase (ENZYMATICS;
P708), 0.5 unit Klenow enzyme (ENZYMATICS; P7060), 10 units T4-PNK
(ENZYMATICS; Y9040) and dNTP (0.125 mM for each) for 30 min at
20 °C. To the end repaired ChIP DNA, 15 unit Klenow fragment (3′–5′
exo, ENZYMATICS; P7010-LC) in a 50 μl reaction containing 1X blue
buffer (ENZYMATICS; B011) and 0.2 mM dATP at 37 °C for 30 min to
generate protruding 3′Abase. Methylated pair-end adapters were
ligated to the DNA fragments using 2400 unit of rapid T4 DNA ligase
(ENZYMATICS; L6030-HC) at 37 °C for 15 min. After puriﬁcation,
200 ng exogenous λ-DNA fragments were added to the samples, and
the sodium bisulﬁte conversion assay (ZYMO D5006) was performed,
followed by 16 cycles of PCR ampliﬁcation that was consisted of
denaturation (94 °C for 15 s), annealing (60 °C for 30 s), extension
(72 °C for 30 s). Then, the PCR products were size-selected on 2%
agarose gel, retaining 250–350 bp DNA fragments. The puriﬁed DNA
(ChIP-BS libraries) was used for cluster generation and standard PE50
sequencing using Illumina Hiseq 2000.
2.4. Processing of ChIP-seq reads
After PE50 sequencing, ChIP-seq readswere processed by the Illumina
base-calling pipeline. Low quality reads that containmore than 30% of ‘N’
or over 10 % of the sequence with low quality per reads were omitted
from the data analysis. The reads were alignedwith the human reference
genome (UCSC hg18) using SOAP (Short Oligonucleotide Analysis
Package) 2.01 [19] with default parameters. Reads that were mapped to
more than one position in the genome were ﬁltered out. Multiple reads
mapping to the same position were counted once to avoid potential
bias from PCR. RSEG algorithm was applied for identiﬁcation of
H3K27me3- and H3K4me3-enriched regions [20]. RSEG is based on
hidden Markov model (HMM) framework including the Baum–Welch
training and posterior decoding, modeling the read counts with a nega-
tive binomial distribution. Subsequently, it uses a two-state HMM for
segmentation of the genome into fore-ground domains and background
domains. To deﬁne an enriched region of H3K27me3 or H3K4me3,
default RSEG settings was used based on bin size of 500 bp, including
that the posterior probability of each bin obtained by HMM decoding is
larger than 0.95 and that the mean of read counts within a region is
above the top 90th percentile of foreground emission distribution. The
adjacent enriched bins were merged.
2.5. Processing of ChIP-BS reads
For histone modiﬁcation signal, same processing was performed
as above for ChIP-seq reads. For DNA methylation signal, ChIP-BS
sequencing reads were aligned to the human reference genome (UCSC
hg18) using an algorithm adapted from the procedure described by Lister
et al. [21]. Because DNAmethylation has strand speciﬁcity, all cytosines in
the reference sequences (“original form”) were replaced in silico by
thymines (“alignment form”) to allow alignment after bisulﬁte conver-
sion. The “original forms” of the sequencing reads were transformed to
cope with the BS treatment nucleotide conversion during the alignment
process using the following criteria: (1) observed cytosines in the
forward read of each read pair were replaced by thymines in silico and
(2) observed guanines in the reverse read of each read pairwere replaced
by adenosines in silico. We then mapped the “alignment form” sequenc-
ing reads to the “alignment form” reference sequences using SOAP 2.01
[19] with default parameters. After mapping, the number of methylated
(C) and unmethylated (T) basecalls at each CpG site within the genome
was used to determine themethylation status of each sequenced cytosine
within a CpG context, both on the forward strand aswell as on the reverse
strand. TheDNAmethylation level of each genomic regionwas deﬁned as
the ratio of supported methylated reads with the sum of methylated and
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with a GC fraction greater than 0.5 and an observed-to-expected ratio of
CpG greater than 0.65 as annotated in UCSC genome browser.
2.6. RNA-seq and data analysis
Total RNA was isolated from BGC-823, AGS cells and YH cells using
the miRNeasy Kit (Qiagen 74104) according to the manufacturer's
protocol. An additional DNase I digestion step was performed to ensure
that the samples were not contaminatedwith genomic DNA. ThemRNA
was enriched by using oligo(dT) magnetic beads. The mRNA was
fragmented into small fragments around 200 bp by mixing with
fragmentation buffer. Then, the ﬁrst strand of cDNA was synthesized
by using random hexamer-primer. The second strand was synthesized
by adding buffer, dNTPs, RNase H and DNA polymerase I. The double
strand cDNA was puriﬁed with magnetic beads. End reparation, 3′-end
addition of adenine (A) nucleotide followed by ligation of adaptors
to the fragment was performed. The fragment was enriched by PCR
ampliﬁcation. The RNA purity was assessed using Agilent bioanalyzer.
Total RNA was converted to cDNA using the NuGEN Ovation RNA-Seq
System according to the manufacturer's protocol (NuGEN, San Carlos,
CA, USA). The cDNA was used for Illumina sequencing library prepara-
tion. DNA fragments were end-repaired to generate blunt ends with 5′
phosphatase and 3′ hydroxyls, and adapters were ligated for paired-
end sequencing on an Illumina Hiseq 2000. The reads were cleaned by
removing low quality data and 50 bp contamination. RNA sequencing
reads were aligned to the reference genome (UCSC hg18) using the
SOAP aligner with the same parameters that were used to process
ChIP sequencing reads. We collated a set of 27,071 RefSeq genes (US
National Center for Biotechnology Information, 20 February 2012
update). Gene expression was calculated using RPKM (Reads Per Kb
per Million reads) [22].
3. Results and discussions
3.1. Variable DNA methylation patterns for H3K27me3-enriched regions
Using ChIP-BS-seq technology, we ﬁrst determined the H3K27me3
status of a normal cell line (YH lymphoblastoid) and three cancer cell
lines (HeLa, BGC-823 and AGS), which are catalyzed by the SET domain
histone methyltransferase EZH2 and have a repressive function. The
ChIP protocol was modiﬁed to obtain the DNA methylation status of
the H3K27me3-bound DNA fragments by using 50-bp pair-end
sequencing instead of conventional single-end sequencing. As a result,
approximately 100 million uniquely mapped reads were obtained for
each of the original four cell lines (Table S1 in additional ﬁle 1). We
found that CpG islands, (+/−500) transcription start sites (TSSs) and
exons were preferentially enriched with H3K27me3 marks in two GC
cell lines (BGC-823 and AGS). In YH cells, H3K27me3 marks were only
preferentially enriched at CpG islands. In contrast, HeLa cells presented
a reverse pattern with highest enrichment of H3K27me3 in the
intergenic regions (Fig. 1A). To conﬁrm this result in HeLa cells and to
check the reproducibility of the ChIP-BS-seq approach, we performed
two independent replicates of ChIP-seq and ChIP-BS-seq and found
that the read densities were correlated well (Pearson R2 = 0.997 for
ChIP-seq; Pearson R2 = 0.994 for ChIP-BS-seq) (Figures S1A and S1B
in additional ﬁle 2). Further analysis on a set of previously published
ChIP-BS-seq data conﬁrmed the observation of distinct H3K27me3
pattern in HeLa cells as well (Figure S2A in additional ﬁle 2) [23].
By applying a RSEG algorithm with default settings [20], we
deﬁned H3K27me3-enriched genomic regions for each cell line
(Table S2, Figure S3 in additional ﬁle 2). In order to guarantee an accurate
measurement of DNA methylation, we calculated methylation levels for
cytosine sites within H3K27me3-enriched regions, requiring at least 4×
depth of deep sequencing. Thereby a high concordance between two
replicates of HeLa samples (Pearson R2 = 0.914) was manifested(Figure S1C in additional ﬁle 2). Similar to the histone modiﬁcation pat-
terns, we observed variable DNA methylation patterns for H3K27me3-
enriched regions in these four cell lines (Fig. 1B). Thus, variable patterns
of both H3K27me3 marks and DNA methylation in different cell popula-
tions were revealed. To testmore cell types, we downloaded ChIP-BS-seq
data proﬁling H3K27me3 marks in another three cell lines (a prostate
cancer cell line LNCaP, a normal prostate epithelial cell line PrEC and a
colon cancer cell line HCT116). These data were previously reported, in
which H3K27me3 pattern of HCT116 cell line was similar to HeLa but it
was different from LNCaP and PrEC [16,17] (Figure S2B in additional ﬁle
2). We then used these data in the subsequent analyses.
3.2. H3K27me3-bound DNA from normal and cancer cell lines diverges in
methylation
Because of the variable patterns were observed in both H3K27me3
marks and methylation of its bound DNA, an intriguing question is
aroused whether cell-type-speciﬁc epigenetic signatures exist in these
cell lines. As majority of H3K27me3 marks were enriched in promoters
containing CGIs in most cell lines, we focused our analysis on the
promoter regions: the upstream 2200 bp and the downstream 500 bp
regions crossing the transcriptional start site (TSS) (as deﬁned in
[24]). In agreement with the variable DNA methylation patterns
among cell lines for all H3K27me3-enriched regions (Fig. 1B), the distri-
bution curve for methylation levels of enriched promoters as well as
exons, introns and intergenic regions showed divergence among these
four cell lines too (Fig. 1C, Figure S4 in additional ﬁle 2). We further
performed clustering analysis for the seven cell lines based on the
average values of cytosine methylation levels in all promoter regions
enriched with H3K27me3 marks. As the result, two normal cell lines
(YH and PrEC) were clustered together and separated from ﬁve cancer
cell lines (Fig. 2A). Moreover, all these cell lines were originated from
different cell lineages. Thus, despite the distinct cellular development
of these cell lines, the above clustering results might suggest that
onco-epigenomic signatures of the DNA methylation bound to the
H3K27me3 marks are different from normal epigenomic signatures.
3.3. Aberrant hypermethylation occurs inH3K27me3-enriched promoter-CGI
regions in cancer cell lines
We next asked what characteristics are common for H3K27me3-
bound DNA methylation among different cancer cell lines that differ
from normal cell lines. Thereby we ﬁrst screened H3K27me3-enriched
genomic regions thatwere overlapped across all seven cell lines, namely
228 commonly enriched genes. We also screened genomic regions
where no H3K27me3 marks were enriched across the seven cell lines,
resulting 5143 corresponding genes. We then analyzed the RNA-seq
data of the four cell lines generated in our study (Table S1 in additional
ﬁle 1) and the downloaded RNA-seq data for HCT116, LNCaP and PrEC
cell lines from previous studies [16,17]. By comparing the expression
levels for these two categories of genes,we found that the transcriptions
of the 228 genes were highly repressed in comparison with the 5143
genes (Figure S5 in additional ﬁle 2), indicating a strong repression
effect on gene transcription exerted by H3K27me3 marks.
We further categorized these genes based on whether CGIs were
incorporated in their promoter or not, i.e. the upstream 2200 bp and
downstream 500 bp around the transcriptional start sites (TSS) [24].
146 (64%) out of the 228 H3K27me3-enriched genes contained CGIs
in their promoters. In comparison, this percentage number is smaller
(45%, 2288 genes) for the 5143 H3K27me3-deﬁcient genes. Sufﬁcient
coverage can be achieved for H3K27me3-enriched genes, ensuring cor-
rect examination of DNA methylation, but not for H3K27me3-deﬁcient
genes. Next, we compared the methylation status between cancer and
normal cell lines with respect to presence of CGIs. A boxplot indicated
that most of the CGIs were highly methylated in ﬁve cancer cell lines
(median methylation level = 47.2%) than in two normal cell lines
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Fig. 1. ChIP-BS-seq DNA methylation proﬁles of H3K27me3-enriched DNA from BGC-823, AGS, YH and HeLa cells. (A) Distribution of H3K27me3-enrichment genome-wide relative
to observed over expected. The expected reads are calculated in a region, e.g. CGI, as (the length of CGI/the length of whole genome)*(total reads). The observed reads are the real read
counts in this CGI region. (B) Distribution proportion of CpGmethylation levels at H3K27me3-marked regions from low (0%) to high (100%)methylation (0.0–1.0). (C) Distribution of CpG
methylation levels at H3K27me3-enriched promoters (TSS Upstream 2 k and downstream 500 bp) from low (0%) to high (100%) methylation (0.0–1.0).
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82 H3K27me3-enriched genes without CGIs promoters were not nota-
bly different in both cancer and normal cell lines. The normal cell lines
even presented slightly higher methylation levels than cancer cell
lines (Fig. 2B).We further performedpair-wise comparison for the aver-
age values of methylation levels of the 146 CGI-containing promoters,
resulting in 127 promoters signiﬁcantly hypermethylated in cancer
cells in comparison with normal cells, while only 1 promoter signiﬁ-
cantly hypomethylated (Chi-square test and Benjamini & Hochberg
FDR-adjusted p-value b 0.05).
We also screened out 98 genes and 58 genes that were enriched
with H3K27me3 marks in their promoter CGIs only in two normal cell
lines and ﬁve cancer cell lines, respectively. Again, the methylation
levels for the 58 genes in cancer cells were signiﬁcantly higher than
the 98 genes in normal cells (Fig. 2C). These observations conﬂicted
with previous observation on mutual exclusion between H3K27me3
and DNA methylation for CGIs [16]. Although their statement might be
largely true for normal cells, we found that some genes enriched with
H3K27me3 marks in diverse cancer cells were aberrantly methylated in
their promoter CGIs.
We also observed somedifference in the cancer-speciﬁcmethylation
proﬁles for the above 127 genes. Most of the genes were highly methyl-
ated in AGS and HCT116 cell lines, but showed low methylation in
LNCaP. In contrast, the BGC-823 and HeLa cell lines showed median
methylation levels in the majority of these genes (Fig. 2D). Therefore,
themethylation frequency of H3K27me3-boundCGIs varied in different
cancer cell populations. For each speciﬁc cancer, there might be only a
set of H3K27me3-bound genes aberrantly hypermethylated in promot-
er CGI, suggesting that other regulatory factors might be important in
this process. For instance, H3K9me3 might be another histone mark
that converses with DNA methylation, probably also with H3K27me3
[25–27]. Furthermore, recent advance indicated that both DNAmethylation and histone modiﬁcations can be directed and mediated
by small RNAs (sRNAs) [28,29], suggesting for potential sequence-
speciﬁcity for the mediation on these epigenetic modiﬁcations. Despite
such complexity of the crosstalk between histonemodiﬁcation andDNA
methylation, these cancer-speciﬁc methylation patternsmight raise the
possibility of usingmethylated DNA bound to the speciﬁc histone mod-
iﬁcations as an epigenetic signature in cancer studies.
3.4. Hypermethylation occurred more frequently in CGIs only bound with
H3K27me3 but not with H3K4me3
We further performed ChIP-BS-seq to assess the presence of the
activating H3K4me3 in YH, AGS and BGC-823 cell lines. As expected,
the H3K4me3 marks were mostly located around the transcription
start sites (TSSs) of known genes in all these cell lines (Figure S6A in
additional ﬁle 2). At the genomic regions enriched with H3K4me3
marks, the DNA methylation levels were extremely low. This result
was not surprising as previous studies supported a strong negative
correlation between DNA methylation and the presence of H3K4me in
several cell types [30,31]. We also found that H3K4me3 marks were
negatively correlated with DNA methylation levels and positively
correlated with the expression of genes that were richly marked by
H3K4me3 (Figure S6B in additional ﬁle 2). Our results reinforced
the observations of antagonistic relationship between H3K4me3 and
DNA methylation for the regulation of gene expression by detecting
methylation status of DNA bound with histone modiﬁcation marks.
A wealth of evidences suggest that PcG-repressed genes are generally
marked by both H3K27me3 and H3K4me3 modiﬁcations [32–34] and
in addition to stem cells, bivalent-modiﬁed domains can also be found
in differentiated cells and cancer cells [35]. Here, we also found that
the co-occurrence of H3K4me3 and H3K27me3 marks in genic regions
is prevalent in our two cancer cell lines and the normal cell line
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genes in RefSeq into four categories: 1) only H3K4me3 highly enriched
(H3K4me3 high), 2) only H3K27me3 highly enriched (H3K27me3
high), 3) both H3K4me3 and H3K27me3 highly enriched (Bivalent)
and 4) neither H3K4me3 nor H3K27me3 highly enriched (Table S2 in
additional ﬁle 1).
We found that themethylation levels of DNA bound with H3K27me3
marks within promoters were considerably divergent among the four
categories of genes. On average, the DNA methylation levels around
TSS remained in a hypomethylated state in the “H3K4me3 high” or the
“Bivalent” category genes both in cancer and normal cells. But in cancer
cells, “H3K27me3 high” category presented a much higher level of DNA
methylation than the other two categories, while in the normal YH cells
the methylation level was limited to a relatively low level (less than
20%) (Fig. 3A), suggesting much less genes were hypermethylated in
H3K27me3-bound regions.
We then examined the distribution of methylation levels of all CGI-
containing promoters in comparison with all CGI-deﬁcient promoters
to the amount of methylated DNA bound to H3K27me3. Comparison
of these two promoter types showed that hypermethylation primarily
occurred in the CGI-containing promoters in the cancer cells, while
in YH cells we found that the CGI-containing promoters were more
commonly hypomethylated (Fig. 3B). Thus, this result again supported
the notion that the increased methylation of H3K27me3 enrichedregion at some promoters in cancer cells was correlated with hyperme-
thylation that occurred in these CGI regions.
3.5. H3K27me3-bound genes with CGI promoter hypermethylation in cell
lines were also hypermethylated in primary cancer tissues
Taken above results together, CGI hypermethylation is associated
with H3K27me3 marks for some genes in cancer cells. However, the
CGI hypermethylation did not exert considerably further repressive
effects on these genes that were already repressed by H3K27me3
marks (Figure S7 in additional ﬁle 2). What role the CGI hypermethyla-
tion had played in the cancer cells is not clear in this stage. However, the
presence of DNA methylation can attract specialized methyl-DNA
binding factors that can then recruit chromatin modiﬁers [36], thus
may change the cell fate extensively. We further performed Gene
Ontology analyses on the 127 genes to see whether these genes were
enriched in particular pathways. As a result, most of these genes were
annotated as genes encoding membrane protein and were enriched in
ion transport or cellular ion homeostasis pathways (Fisher test and BH
adjusted p-value b 0.05) (Table S3 in additional ﬁle 1), which are highly
relevant to carcinogenesis or metastasis as previously reported [37,38].
Then, by looking at the genes that had 65% or greater methylation
level in at least 4 of the 5 cancer cell lines, we found 12 protein-
encoding genes that were relatively conserved for hypermethylation
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Fig. 3. Distribution of methylation levels at promoters in BGC-823, AGS and YH cells. (A) Distribution of average methylation levels detected by H3K27me3-BS in promoters of each
category of genes in three cell lines. The genes were categorized into “H3K27me3 high”, “H3K4me3 high”, “Bivalent” or “Neither” genes, the “Neither” category was not shown. At the
left bottom, box plots show distribution of methylation levels for “H3K27me3 high” and “Bivalent” categories with same color. (B) Distribution of methylation levels of CGI-containing
(CGI+) promoters in comparison with CGI-deﬁcient (CGI-) promoters of H3K27me3 high genes in three cell lines. The bold line is the median value of methylation levels, and the
error bars represent the interquartile range above and below the mean value. Statistical signiﬁcance is indicated by triple asterisks (t-test p-value b 0.001).
209F. Gao et al. / Genomics 103 (2014) 204–210in different cancer types (Table S4 in additional ﬁle 1). ZRANB2-AS1,
CR1L, CH25H and CCDC140 were highly methylated in cell lines of
colon (HCT116), prostate (LNCaP) and stomach (both BGC-823 and
AGS). Other 8 genes (SHE, POU4F1, SYT14, GLT25D2 (COLGALT2),
LHFPL4, NPAS4, PTPRN and NPTX2) were highly methylated in colon
and stomach cancer cell lines, but only moderately methylated in pros-
tate cancer cell line LNCaP. As these 8 genes were nearly non-
methylated in normal prostate PrEC cell line, the possibility of there
being speciﬁcmethylation differences between primary prostate cancer
and normal tissues was still raised (Table S4 in additional ﬁle 1).
Due to the heterogeneity of cancer tissues, diverse cell populations
in cancer tissue might vary in the DNA methylation status. However,
we reasoned that, if the cancer cells comprised of major population
that contain genes with hypermethylated DNA bound to H3K27me3
mark in primary cancer tissues, it could lead to an outcome of abnormal
hypermethylation in this cancer tissue in comparison with normal
tissues. We thus downloaded methylation data for primary colon
adenocarcinoma (COAD), prostate adenocarcinoma (PRAD), stomach
adenocarcinoma (STAD) and from their paired normal controls from
The Cancer Genome Atlas (TCGA) (Table S5 in additional ﬁle 1), in
order to expand our observations from cancer cell lines to primary
cancer tissues. By comparing our cell line methylation data to that of
TCGA patient data, we indeed found that majority of the 12 genes are
signiﬁcantly hypermethylated in primary cancers. The methylation
status was generally consistent between our cell lines and TCGA primary
cancer results. (Figure S8 in additional ﬁle 2).
We also assessed data on themethylation status of these genes from
literature. Of note, aberrant methylation of POU4F1, PTPRN, LHFPL4 and
NPTX2 genes was previously reported in breast cancer [39], ovarian
cancer [40], cervical cancer [41] andpancreatic cancer [42], respectively.
Among the rest of the genes that haven't been reported as having
aberrant methylation in cancer, CCDC140, which also hasn't been
shown to have strong association with cancer, had a very consistent
and signiﬁcant hypermethylation in the TCGA cancer data as compared
with normal controls; raising a high possibility that aberrant methyla-
tion of this gene may be important in cancer as well. For the remaining
genes, therewas also indication that theymight be aberrantlymethylat-
ed in TCGA primary cancers. However, given the cell complexity of
primary cancer tissues, current results from TCGA data might be biased.Further studies applying ChIP-BS-seq technology are needed to com-
pare primary cancer with adjacent normal tissues to further conﬁrm
the observations of aberrant methylation for these genes in cancer cell
lines.
4. Conclusions
Current study by using ChIP-BS-seq revealed the correlation
between H3K27me3 and DNA methylation marks in diverse cancer
cells, as some genes enriched with H3K27me3 marks can be aberrantly
methylated in their promoter CGIs in comparison with normal cells.
Despite of the complexity of the crosstalk between histonemodiﬁcation
and DNA methylation, the H3K27me3-bound hypermethylated CGIs in
speciﬁc genes might be raised as potential new epigenetic signature in
future cancer studies on biomarker discovery and targeted therapeutics.
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